Universal opposition to EU pharmacovigilance fee plan
This article was originally published in SRA
The European Commission is used to hearing mixed views on draft pharmaceutical legislation: after all, that is what the EU consultation and legislative procedures are for. But it must have been taken aback by the results of a recent public consultation on its planned pharmacovigilance fee system that found the "vast majority" of stakeholders did not support the proposal in its current form1.
You may also be interested in...
Hungary is going its own way when it comes to coronavirus vaccines, but its decision to allow the emergency use of the Oxford University/AstraZeneca vaccine may be only a symbolic expression of the government’s growing impatience with the EU.
Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.
The UK government says it will begin a consultation on a future falsified medicines scheme for Great Britain within a year after the passage of new legislation on medicines and medical devices. Moves are also under way to ensure the smooth supply of medicines from GB to Cyprus, Ireland, Malta and Northern Ireland.